Comprehensive Stock Comparison
Compare Caris Life Sciences, Inc. (CAI) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  CAI | 97.0% revenue growth vs REGN's 1.0% |
| Value |  REGN | Lower P/E (17.4x vs 62.1x) |
| Quality / Margins | REGN | 31.4% net margin vs CAI's -66.2% |
| Stability / Safety | REGN | Beta 0.58 vs CAI's 1.09 |
| Dividends | REGN | 0.4% yield; 1-year raise streak; CAI pays no meaningful dividend |
| Momentum (1Y) | REGN | +15.1% vs CAI's -29.1% |
| Efficiency (ROA) | REGN | 11.1% ROA vs CAI's -47.8% |
Who Each Stock Is For
Income & stability
CAIDividend streak 4 yrs, beta 1.09
Growth exposure
CAIRev growth 97.0%, EPS growth -19.3%, 3Y rev CAGR 46.5%
Long-term compounding (10Y)
REGN94.0% 10Y total return vs CAI's -29.1%
Sleep-well-at-night portfolio
CAILower volatility, beta 1.09, Low D/E 0.0%, current ratio 7.85x
Defensive / Recession hedge
REGNBeta 0.58, yield 0.4%, current ratio 4.77x
Business Model
What each company does and how it makes money
Caris Life Sciences is an AI-powered molecular diagnostics company that provides comprehensive cancer profiling services to guide treatment decisions. It generates revenue primarily from molecular testing services for oncology patients — including tissue-based and blood-based profiling — along with pharmaceutical research services for drug development partners. The company's competitive advantage lies in its extensive molecular database and proprietary AI algorithms that analyze complex biomarker data to deliver personalized cancer treatment insights.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
REGN 5CAI 1REGN4/4 metricsREGN5/6 metricsREGN6/8 metricsREGN6/6 metricsREGN2/2 metricsCAI1/1 metricsREGN leads in 5 of 6 categories (Financial Metrics, Valuation Metrics). CAI leads in 1 (Analyst Outlook).
Financial Metrics (TTM)
REGN is the larger business by revenue, generating $14.3B annually — 17.7x CAI's $812M. REGN is the more profitable business, keeping 31.4% of every revenue dollar as net income compared to CAI's -66.2%.
| Metric | CAICaris Life Scienc… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $812M | $14.3B |
| EBITDAEarnings before interest/tax | $70M | $4.2B |
| Net IncomeAfter-tax profit | -$538M | $4.5B |
| Free Cash FlowCash after capex | $33M | $3.2B |
| Gross MarginGross profit ÷ Revenue | +46.2% | +86.3% |
| Operating MarginEBIT ÷ Revenue | +5.6% | +25.7% |
| Net MarginNet income ÷ Revenue | -66.2% | +31.4% |
| FCF MarginFCF ÷ Revenue | +4.0% | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -2.5% |
Valuation Metrics
On an enterprise value basis, REGN's 21.8x EV/EBITDA is more attractive than CAI's 718.4x.
| Metric | CAICaris Life Scienc… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $33.2B | $108.4B |
| Enterprise ValueMkt cap + debt − cash | $32.4B | $92.2B |
| Trailing P/EPrice ÷ TTM EPS | -6.17x | 18.99x |
| Forward P/EPrice ÷ next-FY EPS est. | 62.06x | 17.38x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.00x |
| EV / EBITDAEnterprise value multiple | 718.40x | 21.83x |
| Price / SalesMarket cap ÷ Revenue | 40.89x | 7.55x |
| Price / BookPrice ÷ Book value/share | 57.52x | 2.74x |
| Price / FCFMarket cap ÷ FCF | 496.41x | 26.56x |
Profitability & Efficiency
REGN delivers a 14.4% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-93 for CAI. CAI carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to REGN's 0.09x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs CAI's 5/9, reflecting strong financial health.
| Metric | CAICaris Life Scienc… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -93.2% | +14.4% |
| ROA (TTM)Return on assets | -47.8% | +11.1% |
| ROICReturn on invested capital | — | +12.4% |
| ROCEReturn on capital employed | +7.7% | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.00x | 0.09x |
| Net DebtTotal debt minus cash | -$798M | -$16.2B |
| Cash & Equiv.Liquid assets | $798M | $18.9B |
| Total DebtShort + long-term debt | $169,000 | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | -2.23x | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in REGN five years ago would be worth $17,161 today (with dividends reinvested), compared to $7,093 for CAI. Over the past 12 months, REGN leads with a +15.1% total return vs CAI's -29.1%. The 3-year compound annual growth rate (CAGR) favors REGN at 0.5% vs CAI's -10.8% — a key indicator of consistent wealth creation.
| Metric | CAICaris Life Scienc… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | -26.4% | +1.6% |
| 1-Year ReturnPast 12 months | -29.1% | +15.1% |
| 3-Year ReturnCumulative with dividends | -29.1% | +1.5% |
| 5-Year ReturnCumulative with dividends | -29.1% | +71.6% |
| 10-Year ReturnCumulative with dividends | -29.1% | +94.0% |
| CAGR (3Y)Annualised 3-year return | -10.8% | +0.5% |
Risk & Volatility
REGN is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than CAI's 1.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 95.9% from its 52-week high vs CAI's 46.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CAICaris Life Scienc… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.09x | 0.58x |
| 52-Week HighHighest price in past year | $42.50 | $821.11 |
| 52-Week LowLowest price in past year | $17.15 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +46.7% | +95.9% |
| RSI (14)Momentum oscillator 0–100 | 38.4 | 47.5 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 762K |
Analyst Outlook
Wall Street rates CAI as "Buy" and REGN as "Buy". Consensus price targets imply 57.8% upside for CAI (target: $31) vs 8.8% for REGN (target: $857). REGN is the only dividend payer here at 0.43% yield — a key consideration for income-focused portfolios.
| Metric | CAICaris Life Scienc… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $31.33 | $857.17 |
| # AnalystsCovering analysts | 6 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 4 | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Caris Life Sciences… (CAI) | $294M | $812M | +175.9% |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Caris Life Sciences, Inc.'s revenue grew from $294M (2016) to $812M (2025) — a 11.9% CAGR. Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 2Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Caris Life Sciences… (CAI) | 2.0% | -66.2% | -3351.8% |
| Regeneron Pharmaceu… (REGN) | 18.4% | 31.4% | +70.5% |
Caris Life Sciences, Inc.'s net margin went from 2% (2016) to -66% (2025). Regeneron Pharmaceuticals, Inc.'s net margin went from 18% (2016) to 31% (2025).
Chart 3P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Caris Life Sciences… (CAI) | 0.31 | -3.22 | -1138.7% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Caris Life Sciences, Inc.'s EPS grew from $0.31 (2016) to $-3.22 (2025) — a NaN% CAGR. Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 5Free Cash Flow — 5 Years
Caris Life Sciences, Inc. generated $67M FCF in 2025 (+120% vs 2022). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
CAI vs REGN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CAI or REGN a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 19.0x trailing P/E (17.4x forward), making it the more compelling value choice. Analysts rate Caris Life Sciences, Inc. (CAI) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CAI or REGN?
On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 17.4x.
03Which is the better long-term investment — CAI or REGN?
Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +71.6%, compared to -29.1% for Caris Life Sciences, Inc. (CAI). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +94.0% versus CAI's -29.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CAI or REGN?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus Caris Life Sciences, Inc.'s 1.09β — meaning CAI is approximately 90% more volatile than REGN relative to the S&P 500. On balance sheet safety, Caris Life Sciences, Inc. (CAI) carries a lower debt/equity ratio of 0% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — CAI or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus -66.2% for Caris Life Sciences, Inc. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus 5.6% for CAI. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CAI or REGN more undervalued right now?
On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 17.4x forward P/E versus 62.1x for Caris Life Sciences, Inc. — 44.7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAI: 57.8% to $31.33.
07Which pays a better dividend — CAI or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. CAI does not pay a meaningful dividend and should not be held primarily for income.
08Is CAI or REGN better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc. (REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.58)). Both have compounded well over 10 years (REGN: +94.0%, CAI: -29.1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CAI and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.